REGN: Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance

UK Markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
370.12-6.28 (-1.67%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close376.40
Bid365.00 x 200
Ask389.00 x 100
Day's range368.86 - 379.20
52-week range325.35 - 452.96
Avg. volume895,020
Market cap39.06B
PE ratio (TTM)48.07
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales
    Investor's Business Dailyyesterday

    Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales

    Amgen trumped Regeneron and Sanofi this week as prescriptions of its cholesterol-cutting drug grew.

  • Reutersyesterday

    EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

    A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis. The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis. Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.

  • American City Business Journals3 days ago

    Sanofi Genzyme hit with patent lawsuit over new eczema drug

    Sanofi Genzyme’s next potential blockbuster treatment is running into legal trouble in California, where a unit of Amgen has accused the Cambridge rare disease drugmaker of infringing one of its patents. Immunex Corp., a subsidiary of Amgen (AMGN), filed a complaint in Los Angeles federal court on April 5 claiming that an eczema drug developed by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) infringes a patent related to a failed asthma treatment.